MARK DAVIS: Open Payments
NPI 1265296412 · WALLA WALLA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,361 in 41 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $1,130 · 2025 $1,361
Food & beverage: $1,361
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $345 |
| Neurocrine BioSciences, Inc. | 6 | $255 |
| E.R. Squibb & Sons, L.L.C. | 7 | $214 |
| Janssen Pharmaceuticals, Inc | 7 | $196 |
| Axsome Therapeutics, Inc. | 3 | $160 |
| Supernus Pharmaceuticals, Inc. | 3 | $131 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, INGREZZA, COBENFY, INVEGA SUSTENNA, Auvelity, Qelbree, UZEDY, REXULTI.
Industry payments across WA — which companies pay providers there.
